• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [19081 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2022     NIHR Health Technology Assessment programme Male synthetic sling versus Artificial urinary Sphincter Trial for men with urodynamic stress incontinence after prostate surgery: Evaluation by Randomised controlled trial (MASTER)
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lusotrombopag (thrombocytopenia) - Benefit assessment according to §35a Social Code Book V]
2022     NIHR Health Technology Assessment programme The United Kingdom Transcatheter Aortic Valve Implantation (UK TAVI) Trial
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality for sled prosthesis (knee)]
2022     Agency for Care Effectiveness (ACE) Disease-modifying therapies for treating multiple sclerosis
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for acute lymphoblastic leukaemia
2022     Agency for Care Effectiveness (ACE) Long-acting erythropoiesis-stimulating agents for treating anaemia in chronic kidney disease
2022     Agency for Care Effectiveness (ACE) Tyrosine kinase inhibitors, immune checkpoint inhibitors and everolimus for treating advanced renal cell cancer
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for previously treated advanced gastric cancer
2022     Agency for Care Effectiveness (ACE) Update of MOH list of subsidised drugs to include treatments for various cancer conditions
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [AR101 (peanut allergy) - Addendum to Commission A21-135]
2022     NIHR Health Technology Assessment programme Mammographic surveillance in breast cancer patients aged 50 years or older
2022     Agency for Care Effectiveness (ACE) Tyrosine kinase inhibitors for treating ALK mutation-positive advanced non-small-cell lung cancer
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for prostate cancer
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Search for guidelines on population-based colorectal cancer screening]
2022     Agency for Care Effectiveness (ACE) Cetuximab and panitumumab for treating RAS wild-type colorectal cancer
2022     NIHR Health Technology Assessment programme PRE-EMPT: Preventing Recurrence of Endometriosis by Means of long acting Progestogen Therapy
2022     Agency for Care Effectiveness (ACE) Regorafenib and sunitinib for treating advanced gastrointestinal stromal tumours
2022     NIHR Health Technology Assessment programme Accuracy of glomerular filtration rate (GFR) estimation using creatinine and cystatin C and albuminuria for monitoring disease progression in patients with stage 3 chronic kidney disease: a prospective longitudinal study in a multiethnic population
2022     Agency for Care Effectiveness (ACE) Dabrafenib in combination with trametinib for treating BRAF V600 mutation-positive anaplastic thyroid cancer
2022     Agency for Care Effectiveness (ACE) Eltrombopag for treating immune thrombocytopenia and severe aplastic anaemia
2022     Agency for Care Effectiveness (ACE) Lenvatinib and sorafenib for treating differentiated thyroid cancer
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection - autologous anti-CD19-transduced CD3+ cells]
2022     NIHR Health Technology Assessment programme Ulipristal acetate versus conventional management of heavy menstrual bleeding (HMB; including uterine fibroids): a randomised controlled trial and exploration of mechanism of action (UCON trial)
2022     Agency for Care Effectiveness (ACE) Immune checkpoint inhibitors and BRAK/MEK inhibitors for treating advanced malignant melanoma
2022     NIHR Health Technology Assessment programme Cluster randomised trial of the clinical and cost effectiveness of the i-gel supraglottic airway device versus tracheal intubation in the initial airway management of out of hospital cardiac arrest (Airways-2)
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for previously treated multiple myeloma
2022     Agency for Care Effectiveness (ACE) Everolimus, lanreotide, octreotide and sunitinib for treating advanced neuroendocrine tumours
2022     Agency for Care Effectiveness (ACE) Lenvatinib and sorafenib for treating advanced hepatocellular carcinoma
2022     Agency for Care Effectiveness (ACE) Ranibizumab for treating age-related macular degeneration, diabetic macular oedema and retinal vein occlusion
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Remdesivir (COVID-19) - Benefit assessment according to §35a Social Code Book V]
2022     Agency for Care Effectiveness (ACE) Regorafenib and trifluridine/tipiracil for previously treated metastatic colorectal cancer
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Amivantamab (NSCLC) - Benefit assessment according to §35a Social Code Book V]
2022     Agency for Care Effectiveness (ACE) Botulinum toxin type A for the prophylaxis of headaches in adults with chronic migraine
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abrocitinib (atopic dermatitis) - Benefit assessment according to §35a Social Code Book V]
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for previously treated advanced hepatocellular carcinoma
2022     Agency for Care Effectiveness (ACE) High-strength insulin glargine for treating type 1 and 2 diabetes mellitus
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: optimal use of immunoglobulin in solid organ transplantation]
2022     Agency for Care Effectiveness (ACE) Bevacizumab for treating persistent, recurrent or metastatic cervical cancer
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (breast cancer, triple-negative, locally recurrent/metastatic, in combination with chemotherapy) - Benefit assessment according to §35a Social Code Book V]
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Systematic review of health care interventions in the context of return to work for persons being at risk for long-term sick leave]
2022     Agency for Care Effectiveness (ACE) Aflibercept, bevacizumab and ramucirumab for treating metastatic colorectal cancer
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (oesophageal or gastroesophageal junction carcinoma) - Addendum to Commission A21-144]
2022     Agency for Care Effectiveness (ACE) Carbonic anhydrase inhibitor eye drops for treating open-angle glaucoma or ocular hypertension
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Psycho- and sociotherapeutic interventions: Adolescents - Evidence report on the S3 guideline "Cannabis-related disorders"]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: biologic dose escalation - gastroenterology, rheumatology and dermatology]
2022     Agency for Care Effectiveness (ACE) PARP inhibitors and bevacizumab for treating advanced ovarian cancer
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: evaluation of Afstyla™ (rFVIII) – type A hemophilia]
2022     Agency for Care Effectiveness (ACE) Bevacizumab biosimilar for treating different types of cancers
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (adenocarcinoma of the stomach, the gastro-oesophageal junction or the oesophagus) - 2nd Addendum to Commission A21-146]
2022     NIHR Health Technology Assessment programme The CRASH-3 Trial: Tranexamic acid for the treatment of significant traumatic brain injury
2022     Center for Evidence-based Practice (CEP) Restrictive red blood cell (RBC) transfusion thresholds: update
2022     Agency for Care Effectiveness (ACE) Tofacitinib, ustekinumab and vedolizumab for treating inflammatory bowel disease
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ertugliflozin (type 2 diabetes mellitus) - Addendum to Commission A21-158]
2022     NIHR Health Technology Assessment programme Dynamic contrast-enhanced CT compared with positron emission tomography CT to characterise solitary pulmonary nodules: the SPUtNIk diagnostic accuracy study and economic modelling
2022     Agency for Care Effectiveness (ACE) Sitagliptin for treating type 2 diabetes mellitus
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sacituzumab govitecan (breast cancer) - Addendum to Commission A21-154]
2022     Swiss Federal Office of Public Health (FOPH) Denosumab (Prolia®) for the treatment of osteoporosis
2022     NIHR Public Health Research (PHR) programme E-health interventions targeting STIs, sexual risk, substance use and mental health among men who have sex with men: four systematic reviews
2022     Agency for Care Effectiveness (ACE) Emicizumab prophylaxis for patients with haemophilia A
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mepolizumab (chronic rhinosinusitis with nasal polyposis) - Addendum to Commission A21-150]
2022     Swiss Federal Office of Public Health (FOPH) Trimonthly vs. monthly use of bone-targeted agents in patients with bone metastases and multiple myeloma
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: organization of medical care and services in long-term care facilities]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pharmacotherapeutic interventions - Evidence report on the S3 guideline "Cannabis-related disorders"]
2022     Swiss Federal Office of Public Health (FOPH) Sedative-hypnotic drugs for the treatment of primary chronic insomnia disorder
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: a look at Québec’s family medicine groups and a proposal to segment the population to support continuous quality improvement approaches based on health needs]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mepolizumab (eosinophilic granulomatosis with polyangiitis) - Addendum to Commission A21-151]
2022     Swiss Federal Office of Public Health (FOPH) Levothyroxine as a treatment for subclinical hypothyroidism
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: organization of care and services for the prevention and management of post COVID-19 conditions]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: helicopter emergency medical services (HEMS) - needs analysis and clientele identification]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (adenocarcinoma of the stomach, the gastro-oesophageal junction or the oesophagus) - 2nd Addendum to Commission A21-146]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: practices for screening or reducing psychological symptoms in individuals with a post-COVID-19 condition]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: molecular profiling of adult solid tumors - Focus Panel (Illumina) – 52 somatic biomarkers analysis]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mepolizumab (hypereosinophilic syndrome) - Addendum to Commission A21-152]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: primary care and service quality indicators for supporting continuous quality improvement in Québec’s family medicine groups]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: Evaluation of Fibryga (human fibrinogen concentrate) – acquired fibrinogen deficiency]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: cervical cancer screening in Québec - recommendations for implementing the human papillomavirus detection test (HPV test) as the primary screening test]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: efficacy of psychosocial interventions for the prevention and treatment of common mental disorders and symptoms]
2022     Norwegian Institute of Public Health (NIPH) Transperineal compared with transrectal biopsy on suspected prostate cancer: a health technology assessment
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: optimal use of cardiac ultrasound in Québec - diagnosing patients with a murmur and monitoring patients with valve diseases (native and prosthetic valves)]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sofosbuvir/velpatasvir (chronic hepatitis C in children 3 to < 6 years of age) - Benefit assessment according to §35a Social Code Book V]
2022     NIHR Health Technology Assessment programme Effective Treatments for Thoracic Aortic Aneurysms (ETTAA study): a prospective cohort study
2022     NIHR Health Technology Assessment programme Pre-hospital and emergency department treatment of convulsive status epilepticus in adults: an evidence synthesis
2022     Ontario Health Mechanical thrombectomy for acute and subacute blocked arteries and veins in the lower limbs
2022     Norwegian Institute of Public Health (NIPH) [Transcranial direct current stimulation for depression and aphasia. A health technology assessment]
2022     NIHR Health Technology Assessment programme A large randomised assessment of the relative cost-effectiveness of different classes of drugs for Parkinson's disease (PD MED)
2022     Norwegian Institute of Public Health (NIPH) [Overdose warning systems: a single technology assessment - mapping]
2022     Health Information and Quality Authority (HIQA) HTA of the addition of severe combined immunodeficiency (SCID) to the National Newborn Bloodspot Screening Programme
2022     Agency for Care Effectiveness (ACE) Negative pressure wound therapy for wound management in patients with diabetes (type 1 and 2)
2022     NIHR Health Technology Assessment programme Telaprevir for the treatment of genotype 1 chronic hepatitis C
2022     NIHR Health Technology Assessment programme Pre-eclampsia in Hospital: Early Induction or Expectant management (PHOENIX)
2022     Agency for Care Effectiveness (ACE) Brentuximab vedotin for treating T-cell lymphoma
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sotorasib (NSCLC) - Benefit assessment according to §35a Social Code Book V]
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for treating advanced urothelial carcinoma
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcervical radiofrequency ablation with intrauterine ultrasound guidance for uterine fibroids - Addendum to commission H21-14]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: classification of thickened liquids for dysphagia]
2022     Agency for Care Effectiveness (ACE) Ruxolitinib for treating polycythaemia vera
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Implantation via injection under endoscopic ultrasound guidance of 32P-labeled microparticles for unresectable, locally advanced pancreatic tumours - Addendum to commission H21-13]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: evaluation of HyQvia™ (human normal immunoglobulin 10% and hyaluronidase) – primary and secondary immunodeficiency]
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for treating early or advanced HER2-positive breast cancer